We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Vital Technological Breakthrough Could Help Diagnose Long-Term Effects of COVID-19

By LabMedica International staff writers
Posted on 01 Sep 2022

With no current framework or diagnostic tools, patients suffering from the effects of COVID-19 and long COVID-19 present general practitioners with a major health challenge. More...

Now, a new discovery will aid the diagnosis of debilitating symptoms that can include severe headaches, extreme exhaustion, heart palpitations and brain fog. The discovery comes in the form of a new diagnostic tool that could be easily deployed in medical practices across the world, at low cost.

Eighteen months ago, researchers at Murdoch University (Perth, Australia) used multi-million-dollar nuclear magnetic resonance (NMR) technology to identify new diagnostic molecular biomarkers that tell if someone has the disease, without the need to detect the disease itself. They then used this work to develop an inexpensive clinical NRM that general practitioners can use to detect vital blood markers to predict the long-term effects of the conditions. The technology uses a specially designed set of radio pulses to extract signals from highly specific biomarker signals (from inflammatory glycoprotein markers and fats bound to lipoproteins) that gives a rapid diagnosis in approximately a minute. The researchers believe that their findings represent a translational triumph that will ultimately benefit COVID-19 patients in clinics throughout the world, as well as have the possibility for application across many other diagnostic areas including cardiovascular disease.

“We only discovered these signals about 18 months ago using a more expensive NRM instrument, but with some pulse sequence modifications, we are now able to get identical results on small machines that costs one tenth of the price,” said Professor Jeremy Nicholson, Director of the ANPC and Pro Vice Chancellor for the Health Futures Institute. “We think this technology (low field NMR spectroscopy) will probably have many other clinical applications in the future and may be of particular value in monitoring some of the residual effects of long COVID in individual patients.”

“It ticks all the boxes for a successful translational technology: low costs, low maintenance, no specialist required and no need for complex algorithms to understand the data,” said Professor Julien Wist from the ANPC who believes the technological advancement has many benefits, including cutting costs.

 

 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.